(Q81933467)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18773247%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

title

Radioisotopic localization of (90)Yttrium-ibritumomab tiuxetan in patients with CD20+ non-Hodgkin's lymphoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18773247%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

author name string

S A Jacobs

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18773247%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

A M Harrison

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18773247%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

S H Swerdlow

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18773247%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

K A Foon

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18773247%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

N Avril

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18773247%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

N Vidnovic

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18773247%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

J Joyce

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18773247%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

N DeMonaco

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18773247%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

K S McCarty

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18773247%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

publication date

5 September 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18773247%20AND%20SRC:MED&resulttype=core&format=json

Molecular Imaging and Biology

13 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18773247%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18773247%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18773247%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

page(s)

39-45

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18773247%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11307-008-0170-3

13 January 2020

exact match

0 references

cites work

Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma

1 reference

12 December 2020

Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.

1 reference

12 December 2020

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

12 December 2020

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

1 reference

12 December 2020

Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging

1 reference

12 December 2020

Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier

1 reference

12 December 2020

Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography

1 reference

12 December 2020

Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice

1 reference

12 December 2020

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

1 reference

12 December 2020

Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines

1 reference

12 December 2020

Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation

1 reference

12 December 2020

In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.

1 reference

12 December 2020

Radiolabeled antibody therapy of B-cell lymphomas

1 reference

12 December 2020

Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression

1 reference

12 December 2020

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

12 December 2020

From the bench to the bedside: ways to improve rituximab efficacy.

1 reference

12 December 2020

Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.

1 reference

12 December 2020

Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes

1 reference

12 December 2020

Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab

1 reference

12 December 2020

Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells

1 reference

12 December 2020

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma

1 reference

12 December 2020

Concepts in radioimmunotherapy and immunotherapy: Radioimmunotherapy from a Lym-1 perspective

1 reference

12 December 2020

Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma

1 reference

12 December 2020

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma

1 reference

12 December 2020

Radioimmunotherapy for lymphoma

1 reference

12 December 2020

The epitope recognized by rituximab

1 reference

12 December 2020

Correspondence re: T. Davis et al., therapy of B-cell lymphoma with anti-CD20 antibodies can result in loss of CD20 antigen expression. Clin. Cancer Res., 5: 611-615, 1999

1 reference

12 December 2020

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59

1 reference

12 December 2020

Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study

1 reference

12 December 2020

Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas

1 reference

12 December 2020

Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

1 reference

12 December 2020

Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma

1 reference

12 December 2020

CD20: a regulator of cell-cycle progression of B lymphocytes

1 reference

12 December 2020

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

1 reference

12 December 2020

Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?

1 reference

12 December 2020

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

1 reference

12 December 2020

10.1007/S11307-008-0170-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18773247%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

1 reference